Recent studies show that combining cytarabine with drugs that target epigenetic modifiers (i.e. DNMT1 and HDAC inhibitors) may be a promising new strategy for AML treatment [55, 56]. The gene discussed is HDAC9; the disease is acute myeloid leukemia.